Literature DB >> 2457668

Thyroxine-dependent modulation of natural killer activity.

M Provinciali1, M Muzzioli, N Fabris.   

Abstract

The influence of "in vitro" treatment with thyroia hormones on basal or lymphokine-induced NK cytotoxicity was analyzed in Balb/c mice using YAC-1 as target cells in a 51 Cr release assay. "In vitro" treatment with IFN or IL-2 causes a considerable increase of the natural cytotoxic activity of spleen cells from young-middle aged mice. An additive effect is observed when the two lymphokines are administered simultaneously. "In vitro" spleen cells preincubation with thyroxine increases NK citotoxic activity induced by IFN but it does not modify the basal activity or that induced by IL-2. Furthermore, thyroxine was able to significantly amplify even the maximal boosting effect induced by the simultaneous addition of both IFN and IL-2. These findings suggest a role for thyroid hormones in the modulation of natural cell-mediated citotoxicity and particularly in the espression of NK cell sensitivity to IFN.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2457668

Source DB:  PubMed          Journal:  J Exp Pathol        ISSN: 0730-8485


  4 in total

1.  Modulation of lymphoid cell sensitivity to interferon by thyroid hormones.

Authors:  M Provinciali; N Fabris
Journal:  J Endocrinol Invest       Date:  1990-02       Impact factor: 4.256

2.  Defective response of natural killer activity to thyroxine in Graves' disease.

Authors:  M S Lee; W S Hong; S W Hong; J O Lee; T W Kang
Journal:  Korean J Intern Med       Date:  1990-07       Impact factor: 2.884

3.  Possible stimulation of anti-tumor immunity using repeated cold stress: a hypothesis.

Authors:  Nikolai A Shevchuk; Sasa Radoja
Journal:  Infect Agent Cancer       Date:  2007-11-13       Impact factor: 2.965

Review 4.  Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher.

Authors:  Daniela Gallo; Eliana Piantanida; Matteo Gallazzi; Luigi Bartalena; Maria Laura Tanda; Antonino Bruno; Lorenzo Mortara
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-17       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.